These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8724697)

  • 1. A review of the costs, cost-effectiveness and third-party charges of bone marrow transplantation.
    Westerman IL; Bennett CL
    Stem Cells; 1996 May; 14(3):312-9. PubMed ID: 8724697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: what do we know?
    Waters TM; Bennett CL; Pajeau TS; Sobocinski KA; Klein JP; Rowlings PA; Horowitz MM
    Bone Marrow Transplant; 1998 Apr; 21(7):641-50. PubMed ID: 9578302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of cost analysis in the evaluation of the development of medical technology. The case of allogenic stem-cell transplantation].
    Groot MT; van Agthoven M; Löwenberg B; Willemze R; Uyl-de Groot CA
    Ned Tijdschr Geneeskd; 2004 Mar; 148(10):480-4. PubMed ID: 15042895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Organ transplantation and the inevitable debate as to what constitutes a basic health care benefit.
    Evans RW
    Clin Transpl; 1993; ():359-91. PubMed ID: 7918169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative study of the costs for two hematopoietic cell specimen collections: cytapheresis and bone marrow collection].
    Le Corroller AG; Macquart-Moulin G; Auquier P; Faucher C; Chabannon C; Blache JL; Blaise D; Novakovitch G; Maraninchi D; Moatti JP
    Rev Epidemiol Sante Publique; 1996 Apr; 44(2):133-43. PubMed ID: 8693170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bottom-up analysis of the case costs of stem cell transplantation and selected chemotherapies].
    Stäbler W; Wagner B
    Klin Padiatr; 2003; 215(3):179-84. PubMed ID: 12778360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beware the Medical-Industrial Complex.
    Stevens CW; Glatstein E
    Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical care collection or recovery--VA. Proposed rule.
    Fed Regist; 1998 Oct; 63(197):54756-65. PubMed ID: 10185829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical care collection or recovery. Department of Veterans Affairs. Final rule.
    Fed Regist; 1999 Apr; 64(80):22675-83. PubMed ID: 10558484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood progenitor cell transplantation: economic issues.
    Yee GC
    Pharmacotherapy; 1998; 18(1 Pt 2):9S-16S. PubMed ID: 9473174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative cost analysis of autologous peripheral blood progenitor cell and bone marrow transplantation in pediatric patients with malignancies.
    Vicent MG; Madero L; Chamorro L; Madero R; Diaz MA
    Haematologica; 2001 Oct; 86(10):1087-94. PubMed ID: 11602415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of methadone maintenance.
    Barnett PG; Hui SS
    Mt Sinai J Med; 2000; 67(5-6):365-74. PubMed ID: 11064486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost analysis of the introduction of PBPC for autologous transplantation: effect of switching from bone marrow (BM) to peripheral blood progenitor cells (PBPC).
    Bredeson C; Malcolm J; Davis M; Bence-Bruckler I; Kearns B; Huebsch L
    Bone Marrow Transplant; 1997 Nov; 20(10):889-96. PubMed ID: 9404932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Economic evaluation of blood stem-cells autologous transplantation].
    Corroller AG; Fortanier C; Faucher C; Blaise D; Moatti JP
    Bull Cancer; 2001 Sep; 88(9):893-9. PubMed ID: 11604363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European perspective on the costs and cost-effectiveness of cancer therapies.
    Drummond MF; Mason AR
    J Clin Oncol; 2007 Jan; 25(2):191-5. PubMed ID: 17210939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation.
    Bennett C; Waters T; Stinson T; Almagor O; Pavletic Z; Tarantolo S; Bishop M
    Bone Marrow Transplant; 1999 Sep; 24(5):555-60. PubMed ID: 10482942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost analysis of treatments for severe combined immunodeficiency patients caused by adenosine deaminase deficiency: comparison of gene therapy and bone marrow transplantation.
    Imai H
    Hokkaido Igaku Zasshi; 1998 Mar; 73(2):137-45. PubMed ID: 9612707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic winners and losers after introduction of an effective new therapy depend on the type of payment system.
    Weintraub WS; Warner CD; Mauldin PD; Becker ER; Gomes D; Cook J; Kosinski A; Boccuzzi S
    Am J Manag Care; 1997 May; 3(5):743-9. PubMed ID: 10169536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost comparative study of autologous peripheral blood progenitor cells (PBPC) and bone marrow (ABM) transplantations for non-Hodgkin's lymphoma patients.
    Woronoff-Lemsi MC; Arveux P; Limat S; Deconinck E; Morel P; Cahn JY
    Bone Marrow Transplant; 1997 Dec; 20(11):975-82. PubMed ID: 9422478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.